Our research interests center on pancreatic cancer and tumors of neuroendocrine origin are amongst the most challenging neoplasms to diagnose and treat. Due to their relative rarity and complex pathogenesis, few advances in research have translated into improved clinical outcome. Our work is currently focused on studying tumor biology and signaling mechanisms as they relate to proliferation and development of metastasis. In particular, we are interested in identifying novel molecular targets involved in the development and progression of pancreatic and neuroendocrine tumors. In collaboration with the departments of Drug Discovery and Experimental Therapeutics, we will design and develop new anticancer drugs targeting oncogenic signaling pathways vital to tumor progression, and translate these discoveries into new treatments which are tested in hypothesis-driven clinical trials.